Literature DB >> 23389700

Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Paraskevi Detopoulou1, Tzortzis Nomikos, Elizabeth Fragopoulou, Christina Chrysohoou, Smaragdi Antonopoulou.   

Abstract

Heart failure (HF) is a complex syndrome with cardiac, renal, neurohormonal and sympathetic nervous system's manifestations, the pathogenesis of which among others is connected to inflammation. PAF has local and systemic effects pertaining to HF progression since it causes a negative inotropic effect, it induces arrhythmias, it induces apoptosis and it is involved in inflammation and atherosclerosis. In the present review the role of PAF in HF will be thoroughly presented along with the relevant data on PAF enzymes and the potential role of PAF metabolic circuit as a novel pharmacological target.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23389700     DOI： 10.1007/s11897-013-0131-2

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  92 in total

Review 1.  Anti-inflammatory therapy for heart failure.

Authors:  Akira Matsumori
Journal:  Curr Opin Pharmacol       Date:  2004-04       Impact factor: 5.547

2.  Molecular and cellular actions of platelet-activating factor in rat heart cells.

Authors:  C V Massey; T A Kohout; S T Gaa; W J Lederer; T B Rogers
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes.

Authors:  G M Wahler; D E Coyle; N Sperelakis
Journal:  Mol Cell Biochem       Date:  1990-03-05       Impact factor: 3.396

4.  Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta.

Authors:  R Feliste; B Perret; P Braquet; H Chap
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

5.  The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy.

Authors:  L Liu; S P Zhao
Journal:  Int J Cardiol       Date:  1999-04-30       Impact factor: 4.164

Review 6.  Role of platelet-activating factor in cardiovascular pathophysiology.

Authors:  G Montrucchio; G Alloatti; G Camussi
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

7.  Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias.

Authors:  I Cakici; N Mataraci; S Ersoy; B Tunçtan; N Abacioğlu; I Kanzik
Journal:  Pharmacol Toxicol       Date:  1995-06

8.  Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor.

Authors:  Takeshi Harayama; Hideo Shindou; Rie Ogasawara; Akira Suwabe; Takao Shimizu
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

9.  Arrhythmias caused by platelet activating factor.

Authors:  B F Hoffman; S D Guo; S J Feinmark
Journal:  J Cardiovasc Electrophysiol       Date:  1996-02

10.  Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells.

Authors:  R Heller; F Bussolino; D Ghigo; G Garbarino; G Pescarmona; U Till; A Bosia
Journal:  Biochem Pharmacol       Date:  1992-07-22       Impact factor: 5.858
View more
  8 in total

Review 1.  Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.

Authors:  Elisabetta Damiani; Stephen E Ullrich
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

2.  LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d.

Authors:  Haihai Liang; Zhenwei Pan; Xiaoguang Zhao; Li Liu; Jian Sun; Xiaomin Su; Chaoqian Xu; Yuhong Zhou; Dandan Zhao; Bozhi Xu; Xuelian Li; Baofeng Yang; Yanjie Lu; Hongli Shan
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

Review 3.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

Review 4.  Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.

Authors:  Paraskevi Detopoulou; Constantinos A Demopoulos; Smaragdi Antonopoulou
Journal:  Nutrients       Date:  2021-01-30       Impact factor: 5.717

5.  Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

Authors:  Dongdan Zheng; FanFang Zeng; Anping Cai; Huocheng Liao; Ling Liu; Ruofeng Qiu; Rulin Xu; Chun Xiao; Weiyi Mai
Journal:  Lipids Health Dis       Date:  2014-03-01       Impact factor: 3.876

6.  Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.

Authors:  Limin Feng; Ying Zhao; Guofang Feng; Yu Chen
Journal:  Lipids Health Dis       Date:  2014-06-28       Impact factor: 3.876

7.  A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach.

Authors:  Junzeng Fu; Liping Chang; Amy C Harms; Zhenhua Jia; Hongtao Wang; Cong Wei; Li Qiao; Shuyan Tian; Thomas Hankemeier; Yiling Wu; Mei Wang
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

8.  Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease.

Authors:  Saranya Ravi; Robert N Schuck; Eleanor Hilliard; Craig R Lee; Xuming Dai; Kaitlin Lenhart; Monte S Willis; Brian C Jensen; George A Stouffer; Cam Patterson; Jonathan C Schisler
Journal:  Am J Pathol       Date:  2017-11-16       Impact factor: 4.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.